Most Read Articles
Dr. Carol Tan, 2 years ago
A novel vaccine against dengue has been found to be effective and safe, based on a randomized controlled trial conducted by Dr Maria Rosario Capedeng, et al.
one year ago
Peak nasal inspiratory flow is as favourable as formal rhinomanometry as a marker of objective nasal patency but is cheaper, simpler, and more appropriate for serial measurements and home use according to a review.
2 years ago
Immunosuppression with basiliximab is safe and effective in liver transplantation for patients with hepatitis B virus-related diseases, findings from a single-centre study showed.
Pank Jit Sin, one year ago
The launch of the first dengue vaccine is expected to be underway in Malaysia, with regulatory processes being the remaining hurdle in its release. 

Tedizolid may be effective in MRSA-associated skin infections

3 months ago

The novel oxazolidinone tedizolid appears to be clinically superior to vancomycin and comparable with other monotherapy drugs in treating serious skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), according to a systematic review and network meta-analysis.

Tedizolid has been shown in phase III noninferiority trials to have a favourable tolerability profile and is as effective as linezolid against a wide range of Gram-positive pathogens in the treatment of acute bacterial skin and skin structure infections (ABSSSI). [Antimicrob Agents Chemother 2015;59:864-71]

A total of 10 databases were searched for eligible studies consisting of randomized clinical trials (RCTs) published in English that investigated the efficacy of tedizolid or other established antimicrobials (namely, vancomycin, linezolid, daptomycin, teicoplanin, tigecycline, ceftaroline or telavancin) as monotherapy in adults with suspected or documented MRSA-ABSSSI, or complicated skin and skin structure infections (cSSSI).

Outcome measures included clinical response rate at end of therapy (EOT), post-therapy evaluation (PTE) or test-of-cure (TOC) assessment as well as serious adverse events (AEs) leading to discontinuation of treatment.

Of the 3,618 identified records, 15 RCTs were included for analysis. Tedizolid was shown to be superior in terms of clinical response at EOT (odds ratio [OR], 1.7) and had higher odds of clinical response at PTE or TOC (OR, 1.6) compared with vancomycin, but not with other comparators. No difference was observed among all treatments for discontinuation due to AEs.

“These findings suggest that tedizolid provides an alternative option for the management of serious skin infections caused by suspected or documented MRSA,” said researchers, adding that caution must be observed in interpreting the study results.
Editor's Recommendations
Most Read Articles
Dr. Carol Tan, 2 years ago
A novel vaccine against dengue has been found to be effective and safe, based on a randomized controlled trial conducted by Dr Maria Rosario Capedeng, et al.
one year ago
Peak nasal inspiratory flow is as favourable as formal rhinomanometry as a marker of objective nasal patency but is cheaper, simpler, and more appropriate for serial measurements and home use according to a review.
2 years ago
Immunosuppression with basiliximab is safe and effective in liver transplantation for patients with hepatitis B virus-related diseases, findings from a single-centre study showed.
Pank Jit Sin, one year ago
The launch of the first dengue vaccine is expected to be underway in Malaysia, with regulatory processes being the remaining hurdle in its release.